Results 11 to 20 of about 13,452 (195)

FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy

Proceedings of the National Academy of Sciences of the United States of America, 2022
Significance Tumor immunotherapy synergized with radiotherapy (RT) has become promising for eradicating multiple advanced tumors. However, accompanying treatment-related detrimental events in normal tissues has been the dark side of the combination ...
Xiaolin Shi, Yiwei Yang, Wei Zhang, Jianxin Wang, D. Xiao, Huan Ren, Tingting Wang, F. Gao, Zhen Liu, K. Zhou, Peng Li, Zheng Zhou, P. Zhang, Xuming Shen, Yu Liu, Jianheng Zhao, Zhongmin Wang, Fenju Liu, C. Shao, Dai Wu, Haowen Zhang   +20 more
semanticscholar   +1 more source

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

Journal for ImmunoTherapy of Cancer, 2020
Background Radioimmunotherapy has a promising antitumor effect in hepatocellular carcinoma (HCC), depending on the regulatory effect of radiotherapy on tumor immune microenvironment.
Hui Wang, Yan Huang, Jian Wang, Hailong Sheng, Yazhi Xiao, Zhenru Zhu, Mengying Shen, Peitao Zhou, Zeqin Guo, Wencong Dai, Wanjun Zhang, Jingyuan Sun, Chuanhui Cao   +12 more
doaj   +1 more source

Pretargeting: A Path Forward for Radioimmunotherapy

Journal of Nuclear Medicine, 2022
Pretargeted radioimmunodiagnosis and radioimmunotherapy aim to efficiently combine antitumor antibodies and medicinal radioisotopes for high-contrast imaging and high–therapeutic-index (TI) tumor targeting, respectively.
S. Cheal, Sebastian K. Chung, B. Vaughn, N. Cheung, S. Larson   +4 more
semanticscholar   +1 more source

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer

Cell Death Discovery, 2022
Radiation resistance and unsatisfactory efficacy of radioimmunotherapy are important barriers to non-small cell lung cancer (NSCLC) treatment. The impacts of anlotinib on radiation and tumor immune microenvironment (TIME) in NSCLC remain to be resolved ...
Dong Han, Jiajia Zhang, Yawei Bao, Lei Liu, Ping Wang, Dong Qian   +5 more
doaj   +1 more source

Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer

Frontiers in Immunology, 2023
Colorectal cancer (CRC) is one of the most common cancers, with a high mortality rate, and is a major burden on human health worldwide. Gut microbiota regulate human immunity and metabolism through producing numerous metabolites, which act as signaling ...
Hanghang Yuan, Hanghang Yuan, Ruirui Gui, Ruirui Gui, Zhicheng Wang, Fang Fang, Hongguang Zhao   +6 more
doaj   +1 more source

Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression

Biomaterials Research, 2022
Background Astatine-211 is an α-emitter with high-energy α-ray and high cytotoxicity for cancer cells. However, the targeted alpha therapy (TAT) also suffers from insufficient systematic immune activation, resulting in tumor metastasis and relapse ...
Jia-Jia Zhang, Feize Li, Yu-Zhen Yin, Ning Liu, Mengqin Zhu, Han Zhang, Weihao Liu, Mengdie Yang, ShanShan Qin, Xin Fan, Yuanyou Yang, Kun Zhang, Fei Yu   +12 more
semanticscholar   +1 more source

Antibody Engineering for Nuclear Imaging and Radioimmunotherapy

Journal of Nuclear Medicine, 2022
Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals.
Cindy Rodriguez, Samantha Delaney, Samantha M. Sarrett, Outi M Keinänen, Brian M. Zeglis   +4 more
semanticscholar   +1 more source

Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer

Proceedings of the National Academy of Sciences of the United States of America, 2022
Significance Neuroendocrine prostate cancer (NEPC) is a highly aggressive variant of prostate cancer with few meaningful treatment options. As a result, patients have a poor prognosis once diagnosis is confirmed.
Joshua A. Korsen, J. A. Gutierrez, Kathryn M. Tully, L. Carter, Zachary V. Samuels, Samantha Khitrov, J. Poirier, C. Rudin, Yu Chen, M. Morris, L. Bodei, N. Pillarsetty, Jason S. Lewis   +12 more
semanticscholar   +1 more source

Radioimmunotherapy‐induced intratumoral changes in cervical squamous cell carcinoma at single‐cell resolution

Cancer Communications, 2022
Dear Editor, Increasing numbers of studies have revealed the immunomodulating effects of radiotherapy when combinedwith immune checkpoint inhibitors, as radioimmunotherapy has proven to be a promising treatment [1].
Chao Liu, Hao Yu, Rui Huang, Tian-Run Lei, Xiaohui Li, Ming Liu, Qingyu Huang, Qilian Du, L. Xing, Jinming Yu   +9 more
semanticscholar   +1 more source

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor

Frontiers in Oncology, 2021
Desmoplastic small round cell tumor (DRSCT) is a highly aggressive primitive sarcoma that primarily affects adolescent and young adult males. The 5-year survival rate is 15-30% and few curative treatment options exist.
Madelyn Espinosa-Cotton, Nai-Kong V. Cheung   +1 more
doaj   +1 more source